WO2005121795A1 - 非特異反応が抑制された免疫測定方法および試薬 - Google Patents
非特異反応が抑制された免疫測定方法および試薬 Download PDFInfo
- Publication number
- WO2005121795A1 WO2005121795A1 PCT/JP2005/010882 JP2005010882W WO2005121795A1 WO 2005121795 A1 WO2005121795 A1 WO 2005121795A1 JP 2005010882 W JP2005010882 W JP 2005010882W WO 2005121795 A1 WO2005121795 A1 WO 2005121795A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- enzyme
- antibody
- labeled
- reagent
- sample
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
Definitions
- the present invention relates to a method and an immunoassay for an immunological quantification method of a measurement object in which nonspecific reaction is suppressed, an immunological quantification method of a measurement object in which nonspecific reaction is suppressed, and an object to be measured.
- the present invention relates to a method for suppressing a non-specific reaction in a method for immunological quantification of A.
- HAMA human anti-mouse antibodies
- HAMA type I has been sensitized to mouse protein! ⁇ ⁇ ⁇ It is produced in human blood
- HAMA type II is animal breeder It is produced in people who are in contact with mice, such as in mice, and in those who receive mouse proteins such as mouse antibodies.
- HAMA is a non-specific factor that is a problem when using mouse antibodies in immunological quantification methods.It is known that HAMA causes errors in the measurement system and makes it impossible to measure accurate values. ing. Therefore, there is a need for the development of a measurement method that gives an accurate quantitative value, which may give erroneous judgments when monitoring the disease state, etc. with the quantitative value of the target substance obtained by the immunoassay method for quantifying the target substance in the sample. It has been demanded.
- Interleukin-1 2 (hereinafter referred to as IL-2) has a site power of 133 amino acids It is mainly produced from CD4 + and CD8 + T cells. It is also produced from natural killer cells ( ⁇ cells). IL-2 is mainly involved in the activation of the immune system and has various physiological activities. For example, IL-2 acts on ⁇ -cells, ⁇ -cells, ⁇ -cells, LAK cells (lymphokine activated killer cells), macrophages, neutrophils, etc., as a progression factor that promotes the cell cycle.
- IL-2 acts on ⁇ -cells, ⁇ -cells, ⁇ -cells, LAK cells (lymphokine activated killer cells), macrophages, neutrophils, etc.
- the receptor for IL-2 (hereinafter, referred to as IL-2R) is composed of an ⁇ -chain, a chain, and a ⁇ -chain! It is known that two receptors (hereinafter referred to as SIL-2R) are present in blood.
- SIL-2R is activated ⁇ Because it is produced by cells and ⁇ cells, SIL-2R in the blood rises due to the activation of the immune defense mechanism in the living body and the activation of ⁇ cell lines and ⁇ cell lines It has been reported that Serum SIL-2R levels are high in patients with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and viral infections such as viral hepatitis and acquired immunodeficiency syndrome (AIDS). It has been reported to be one of the indicators of activated lymphocytes in the body.
- autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE)
- viral infections such as viral hepatitis and acquired immunodeficiency syndrome (AIDS). It has been reported to be one of the indicators of activated lymphocytes in the body.
- Serum SIL-2R concentration is clinically used as an index for monitoring disease status in adult T-cell leukemia, and as a measure for non-Hodgkin's lymphoma, as a measure of therapeutic effect, follow-up after remission, and early detection of recurrence. It is being used effectively.
- Patent Document 1 JP-A-61-65162
- Patent Document 2 JP-A-1-254869
- Patent document 3 JP-A-5-188055
- Patent Document 4 JP-A-62-70761
- Non-patent Document 1 Tally's Chemistry, 1999, Vol. 45, 942-95 6 pages
- Non-Patent Document 2 Cancer-Immological Therapy (Cancer Immunolgical Immu notherapy), 1991, Vol. 33, pp. 80-84
- Non-Patent Document 3 Tally's Chemistry, 1990, Vol. 36, p. 1093
- An object of the present invention is to provide an immunological quantification method for a measurement target in which a non-specific reaction is suppressed, a reagent used in an immunological quantification method for a measurement target in which a non-specific reaction is suppressed, and a measurement target
- An object of the present invention is to provide a method for suppressing a non-specific reaction in an immunological quantification method for a substance.
- the present invention relates to the following (1) to (35).
- Immunoassay for quantifying an analyte in a sample using an enzyme-labeled antibody in which an enzyme is bound as a label to a first antibody that specifically binds to the analyte in an aqueous medium
- one or more enzyme-labeled enzymes selected from the group consisting of enzyme-labeled antibodies in which the number of bonds between the first antibody and the enzyme is 1: 1, 1: 2, 1: 3 and 2: 1 respectively
- a non-specific method comprising reacting an enzyme-labeled antibody substantially containing only an antibody with a sample to form an immune complex with an analyte and measuring the enzyme activity of the immune complex. For quantitatively determining an object to be measured in which a reaction is suppressed.
- the immunological quantification method according to (1) comprising a step of forming an immune complex with the measurement object.
- the number of bonds between the first antibody and the enzyme is 1: 1, 1: 2 and 1: 3, respectively (12) to (14)! , A reagent described in any of the above.
- It further contains one or more substances selected from the group consisting of aqueous media, metal ions, salts, saccharides, surfactants, preservatives, proteins and protein stabilizers (12) to (23) ) !, reagent described in any of them.
- An immunological quantification method for quantifying an analyte in a sample using an enzyme-labeled antibody in which an enzyme is bound as a label to a first antibody that specifically binds to the analyte One or more enzyme-labeled antibodies selected from the group consisting of enzyme-labeled antibodies in which the number of bonds between the first antibody and the enzyme is 1: 1, 1: 2, 1: 3 and 2: 1, respectively.
- Non-specific method for immunological quantification of a measurement target which comprises a step of reacting an enzyme-labeled antibody containing substantially only the antibody with the sample to form an immune complex with the measurement target. How to suppress the reaction.
- An antibody in which separation means is bound to a second antibody that specifically binds to an antigen determination site different from the antigen determination site of the measurement target to which the first antibody binds is reacted with the sample.
- a reagent and a reagent for use in an immunological quantification method of a measurement object in which nonspecific reaction is suppressed an immunological quantification method of a measurement object in which nonspecific reaction is suppressed, and A method for suppressing a nonspecific reaction in an immunological quantification method is provided.
- FIG. L Gel filtration column chromatogram of POD-labeled anti-SIL-2R monoclonal F (ab ') antibody
- the non-specific reaction in the present invention is not particularly limited as long as it is a non-specific reaction that can be seen in an immunoassay for a measurement object, but non-specific reactions caused by HAMA and reactions with a labeled enzyme And non-specific reactions caused by the antibodies.
- HAMA and Examples include HAMA type I and HAMA type II.
- Examples of the antibody that reacts with the labeling enzyme include an antibody that reacts with peroxidase and an antibody that reacts with alkaline phosphatase.
- the antibody that reacts with the labeling enzyme in the present invention is an antibody that is used in the immunological assay method of the present invention! Cause a non-specific reaction.
- the sample used in the present invention includes, for example, whole blood, plasma, serum, cerebrospinal fluid, saliva, amniotic fluid, urine, sweat, knee fluid, etc., and preferably whole blood, plasma, serum and the like.
- the measurement object of the present invention is not particularly limited as long as it is a substance that can serve as an antigen, but is preferably an antigen having at least two antigenic determinants.
- examples include sIL-2R, myoglobin known as a marker of myocardial infarction, creatine kinase MB (CK-MB), tropon T and the like.
- the first antibody that forms the enzyme-labeled antibody used in the present invention is not particularly limited as long as it is an antibody that specifically binds to the measurement target, and can be any of polyclonal antibodies and monoclonal antibodies. Antibodies are preferred. In addition, in the present invention, not only antibodies but also Fc parts such as Fab obtained by papain treatment of antibodies, F (ab ') obtained by pepsin treatment, Fab' obtained by pepsin treatment and reduction treatment, etc.
- Antibody fragments that have been removed can also be used.
- F (ab ') is particularly preferred as an antibody fragment.
- the second antibody forming the immobilized antibody used in the present invention any of polyclonal antibodies and monoclonal antibodies, which are not particularly limited as long as they specifically bind to the measurement target, can be used. Potentials Monoclonal antibodies are preferred.
- the second antibody is preferably an antibody that specifically binds to an antigenic determinant different from the antigenic determinant of the measurement target to which the first antibody binds.
- the antibody used in the present invention can be obtained by an ordinary method using a peptide to be measured or a peptide corresponding to its epitope as an antigen, and may be commercially available. Available.
- Examples of the antibody that specifically binds to sIL-2R include, for example, a monoclonal antibody (manufactured by PIERCE) produced by the hybridoma AM92.3, and a monoclonal antibody 7G7 / B6 (manufactured by Pierce; -70761), and can be arbitrarily used as the first antibody or the second antibody, respectively.
- a monoclonal antibody manufactured by PIERCE
- a monoclonal antibody 7G7 / B6 manufactured by Pierce; -70761
- examples of the enzyme that binds to the first antibody include peroxidase (hereinafter abbreviated as POD), alkaline phosphatase, luciferase, 13-D-galactosidase, glucose oxidase and the like. , Peroxidase and alkaline phosphatase are preferred, and peroxidase is particularly preferred.
- POD peroxidase
- alkaline phosphatase a peroxidase derived from horseradish rust, which can also use a peroxidase derived from the herb, is preferable.
- alkaline phosphatase include alkaline phosphatase derived from bovine small intestine.
- the enzyme-labeled antibody in the present invention is one in which an enzyme is bound as a label to a first antibody that specifically binds to an object to be measured, and examples of a binding mode in the binding include a covalent bond.
- the enzyme and the antibody may be directly bonded, or may be indirectly bonded via a linker or the like.
- Examples of the method for preparing the conjugate include the Daltaraldehyde method, the periodic acid method, the maleimide method, and the pyridyl disulfide method (for example, Eiji Ishikawa, Enzyme Immunoassay, published by Medical Shoin, 1987. See), but the preferred method is the maleimide method.
- an antibody which is sulfhydrylated with iminothiolane or the like succinimidyl 4- [N-maleimidomethyl] -cyclohexane-1carboxylic acid (succinimidyl 4-[N-maleimidomethyl] -cyclohexane- 1-carboxylate, SMCC ), N- (6-maleimidocaproyloxy) succinimide [N- (6-maleimidocaproyloxy) succinimide, EMCS] or the like, and can be prepared by mixing with an enzyme which has been subjected to maleimidation.
- the enzyme-labeled antibody used in the present invention is an enzyme-labeled antibody in which a small number of labeled enzyme molecules are bound per antibody molecule, and specifically, the number of bonds between the first antibody and the enzyme is Enzyme-labeled substantially containing only one or a plurality of enzyme-labeled antibodies selected from the group consisting of enzyme-labeled antibodies having a ratio of 1: 1, 1: 2, 1: 3 and 2: 1: An antibody, preferably one or more enzyme-labeled antibodies selected from the group consisting of enzyme-labeled antibodies, wherein the number of bonds between the first antibody and the enzyme is 1: 1, 1: 2 and 1: 3, respectively.
- An enzyme-labeled antibody substantially containing only the antibody, more preferably an enzyme-labeled antibody in which the number of bonds between the first antibody and the enzyme is 1: 1 and 1: 2, respectively.
- An enzyme-labeled antibody substantially containing only one or more enzyme-labeled antibodies selected from the group.
- the labeled antibody may be a mixture of the enzyme-labeled antibody, which is particularly preferable for the enzyme-labeled antibody having a binding force of 1: 1: about 1: 2.
- the ratio of the number of molecules of the enzyme-labeled antibody in which the number of bonds between the first antibody and the enzyme is 1: 1: 2 is preferably 50% or more of the total labeled antibodies, and 70% or more is more preferable. Preferred 90% or more is particularly preferred.
- Such an enzyme-labeled dani antibody is prepared by combining the first antibody with the enzyme by the above-described dartal aldehyde method, periodate method, maleimide method, pyridyl disulfide method, etc.
- the bound first antibody, unreacted enzyme, and antibody are separated using, for example, ion exchange chromatography, gel filtration column chromatography, hydrophobic chromatography, or a combination of these methods. It can be prepared by removing it.
- the immobilized antibody in the present invention is one in which a separation means is bound to a second antibody that specifically binds to an object to be measured.
- the separation means include a substance that specifically binds to the solid phase itself or a substance bound to the solid phase.
- Non-covalent bonding is used when using a solid phase
- covalent bonding is used when using a substance that specifically binds to a substance bound to the solid phase. They may be directly bonded or indirectly bonded via a linker or the like.
- Examples of the combination of the substance bound to the solid phase and the substance specifically bound thereto include a combination of biotin and avidin.
- the solid phase is not particularly limited as long as it is a solid phase on which the second antibody is immobilized and the immunological measurement method of the measurement object can be performed.
- polystyrene such as a microtiter plate is used. Plates, glass or synthetic resin granules (beads), glass or synthetic resin spheres (balls), latex, magnetic particles, various membranes such as nitrocellulose membranes, synthetic resin test tubes, etc.
- the IgG polymer in the present invention is not particularly limited as long as IgG is polymerized.
- MAK33-IgGl / IgGl Poly, MAK33-IgG (2b) / Fab (2a) Poly both are Roche's Gnostics (Roche Diagnostics)].
- the IgG in the present invention is not particularly limited as long as it is an animal IgG, and examples thereof include animal IgG such as mice, rats, hamsters, rabbits, guinea pigs, goats, higgs, -petri, birds, birds, etc. However, mouse IgG is preferred. Animal IgG may be purified or animal serum.
- Examples of the aqueous medium include, for example, deionized water, distilled water, and a buffer, and a buffer, and a buffer is preferable.
- the buffer used in the preparation of the buffer is not particularly limited as long as it has a buffering capacity.
- Examples of pH 1 to 11 include lactate buffer, citrate buffer, acetate buffer, succinate buffer, Phthalate buffer, phosphate buffer, triethanolamine buffer, ethanolamine buffer, lysine buffer, barbitur buffer, imidazole buffer, malate buffer, oxalate buffer, glycine buffer,
- Examples include a borate buffer, a carbonate buffer, a glycine buffer, and a good buffer.
- Examples of the good buffer include 2-morpholinoethanesulfonic acid (MES) buffer, bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane (Bis-Tris) buffer, and tris (hydroxymethyl).
- MES 2-morpholinoethanesulfonic acid
- Bis-Tris bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane
- Tris tris (hydroxymethyl).
- Aminomethane (Tris) buffer N- (2-acetamido) iminoniacetic acid (ADA) buffer, Piperazine- ⁇ , ⁇ '-bis (2-ethanesulfonic acid) (PIPES) buffer, 2- [N- (2-acetamido) amino] ethanesulfonic acid (ACES) buffer, 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO) buffer, 2- [ ⁇ , ⁇ -bis (2-hydroxyethyl) amino ] Ethanesulfonic acid (BES) buffer, 3-morpholinopropanesulfonic acid (MOPS) buffer, 2- ⁇ N- [tris (hydroxymethyl) methyl] amino ⁇ ethanesulfonic acid (TES) buffer, N- (2 -Hydroxyethyl)- ⁇ '-(2-sulfoethyl) piperazine (HEPES) buffer, 3- [ ⁇ , ⁇ -bis (2-hydroxyethyl) amino]-2-hydroxyprop
- the concentration of the buffer solution is not particularly limited as long as it is a concentration suitable for measurement, but is preferably 0.001 to 2.0 mol / L, more preferably 0.005 to 1.0 mol / L, and 0.01 to 0.1 mol / L. Is particularly preferred.
- Examples of the metal ion include a magnesium ion, a manganese ion, and a zinc ion.
- salts examples include sodium salt sodium and potassium salt sodium salt.
- saccharide examples include mannitol and sorbitol.
- the surfactant examples include a nonionic surfactant, a cationic surfactant, an anionic surfactant, an amphoteric surfactant and the like, and a nonionic surfactant is preferred.
- the nonionic surfactant examples include Tween 20 (Tween 20) and Nordet P-40 (NP-40).
- preservatives examples include sodium azide, antibiotics (streptomycin, penicillin, gentamicin, etc.), bioace, Proclin 300, Proxel GXL and the like.
- Protein examples of the protein include bovine serum albumin (BSA), fetal calf serum (FBS), casein, Block Ace TM (manufactured by Dainippon Pharmaceutical Co., Ltd.) and the like.
- BSA bovine serum albumin
- FBS fetal calf serum
- casein Block Ace TM (manufactured by Dainippon Pharmaceutical Co., Ltd.) and the like.
- protein stabilizer examples include peroxidase stabilizing buffer [Peroxidase Stabilizing Buffer, manufactured by DakoCytomation].
- the inactivated enzyme used in the present invention includes the same enzyme as the enzyme used for labeling the enzyme-labeled antibody used in the immunological quantification method of the measurement object of the present invention, that is, the same enzyme derived from the same organism. What is necessary is just to inactivate the active enzyme.
- the immunological quantification method using a POD-labeled antibody, when using an inactive antibody of the POD, and using an alkaline phosphatase-labeled antibody, A product obtained by inactivating the alkaline phosphatase is used.
- the inactivated enzyme may be one bound to a carrier or an antibody, but in this case, the antibody must be one that does not react with the object to be measured or the antibody.
- Inactivation is to completely or substantially eliminate the enzymatic activity involved in the immunological quantification method of the present invention while maintaining the reactivity with an antibody that reacts with a labeled antibody that causes a nonspecific reaction. It can be performed by heat treatment, denaturation treatment with acid or alkali, enzymatic digestion with protease, freeze-thaw treatment, or a combination thereof.
- an inactivated POD can be obtained by treating at 100 to 125 ° C for 10 to 60 minutes.
- An inactive POD is Inactive Poly-POD (Roche's Diagnostics).
- Examples of the inactivated alkaline phosphatase include Scavenger-ALP (manufactured by Oriental Yeast).
- the immunological quantification method of the analyte of the present invention includes the following methods: the number of bindings between the first antibody and the enzyme that specifically binds to the analyte is 1: 1, 1: 2, 1: 3 and 2: 1, respectively.
- Enzyme-labeled antibody which is selected from the group consisting of: one or more enzyme-labeled antibodies selected from the group, and an enzyme-labeled antibody substantially containing only the enzyme-labeled antibody is reacted with the sample to form an immune complex with the analyte.
- the method is not particularly limited as long as the method includes a step and a step of measuring an enzyme activity of an immune complex, and further, an antigen different from an antigen determination site of a measurement target to which the first antibody binds
- a method including a step of reacting a sample with an immobilized antibody in which a separation means is bound to a second antibody that specifically binds to a determination site to form an immune complex with an analyte is preferable.
- the number of bonds between the first antibody and the enzyme is 1: 1, 1: 2 and 1 respectively.
- the labeled antibody is a mixture of the enzyme-labeled antibody, which is particularly preferable for the enzyme-labeled antibody having a binding power of 1: 1: about 1: 2, for the labeled antibody,
- the ratio of the number of molecules of the enzyme-labeled antibody in which the number of bonds between the first antibody and the enzyme is 1: 1: 2 is preferably 50% or more of the total labeled antibodies, and 70% or more is more preferable. Preferred 90% or more is particularly preferred.
- Specific examples of the quantification method include, for example, a sandwich method and a competitive method, but the sandwich method is preferred.
- the sandwich method include a one-step method, a one-step delay method, and a two-step method.
- a more specific example of a method for immunological quantification of a measurement target is a quantification method including the following steps.
- a step of quantifying the measurement target by comparing the enzyme activity measured in step (4) with a calibration curve prepared in advance using a measurement target having a known concentration.
- a step of washing the solid phase after the primary reaction may be added. Further, the step (1) and the step (2) can be performed simultaneously.
- the primary reaction is preferably performed in an aqueous medium.
- the reaction temperature of the primary reaction For example, it is 0 to 50 ° C, preferably 4 to 40 ° C.
- the reaction time of the primary reaction is, for example, 5 minutes to 20 hours.
- a washing solution used for washing the solid phase after the primary reaction for example, phosphate buffered saline (10 mmol / L phosphate buffer containing 0.15 mol / L sodium chloride, pH 7.2, Hereinafter, it is referred to as PBS), and PBS containing a surfactant.
- the surfactant include a nonionic surfactant such as Tween 20.
- the secondary reaction is preferably performed in an aqueous medium.
- the antigenic determinant in the antibody used in the secondary reaction to form the enzyme-labeled antibody (the first antibody) is different from the antigenic determinant in the antibody used in the primary reaction (the second antibody) Is preferred.
- the reaction temperature of the secondary reaction is, for example, 0 to 50 ° C, preferably 4 to 40 ° C.
- the reaction time of the secondary reaction is, for example, 5 minutes to 20 hours.
- the washing solution used for washing the solid phase after the primary reaction includes, for example, the washing solution described above.
- an enzyme is reacted with a substrate of the enzyme, and the generated substance is measured.
- the enzyme activity in the complex can be measured.
- the reaction between the enzyme substrate and the enzyme is preferably performed in an aqueous medium.
- the peroxidase activity in the immune complex can be measured by, for example, an absorbance method, a fluorescence method, a luminescence method, or the like.
- a method for measuring peroxidase activity by the absorbance method for example, peroxidase is reacted with a combination of its base hydrogen peroxide and an oxidative chromogen, and the absorbance of the reaction solution is measured with a spectrophotometer or the like.
- the oxidative color-forming chromogen include a leuco-type chromogen and an oxidative coupling-coloring chromogen.
- a leuco-type chromogen is a substance that is converted into a dye alone in the presence of a peroxidic active substance such as hydrogen peroxide and peroxidase.
- a peroxidic active substance such as hydrogen peroxide and peroxidase.
- a peroxidic active substance such as hydrogen peroxide and peroxidase.
- a peroxidic active substance such as hydrogen peroxide and peroxidase.
- Oxidative coupling color-forming chromogen is a substance that produces a dye by oxidative coupling of two compounds in the presence of a peroxide active substance such as hydrogen peroxide and peroxidase.
- a peroxide active substance such as hydrogen peroxide and peroxidase.
- the combination of the two compounds include a combination of a coupler with an arin (a Trinder reagent) and a combination of a coupler with a phenol.
- the coupler include 4-aminoantipyrine (4-AA) and 3-methyl-2-benzothiazolinone hydrazine.
- the concentration of the peroxide is not particularly limited as long as it is a concentration suitable for the measurement.
- the amount is preferably 1 to 100 kU / L.
- the concentration of the oxidative coloring type chromogen is not particularly limited as long as it is a concentration suitable for measurement, but is preferably 0.01 to 10 g / L.
- a method of measuring peroxidase activity by a fluorescence method for example, A method of reacting the enzyme with its substrate, hydrogen peroxide and a combination of a fluorescent substance, and measuring the intensity of the generated fluorescence.
- the fluorescent substance include 4-hydroxyphenylacetic acid, 3- (4-hydroxyphenyl) propionic acid, and coumarin.
- a method for measuring peroxidase activity by a luminescence method for example, a method of reacting peroxidase with a combination of a substrate thereof, hydrogen peroxide and a luminescent substance, and measuring the intensity of generated luminescence, etc. can give.
- the luminescent substance include luminol.
- alkaline phosphatase activity in the complex can be measured by, for example, a luminescence method.
- a luminescence method for example, a method of reacting alkaline phosphatase with a substrate thereof and measuring the luminescence intensity of generated luminescence with a luminescence intensity meter or the like can be mentioned.
- Substrates for alkaline phosphatase include, for example, 3- (2'-spiroadamantane) -4-methoxy-4- (3-phosphoryloxy) phenyl-1,2-dioxetane 'disodium salt (AMPPD) 2 black mouth - 5- ⁇ 4-methoxy-spiro [1,2 Jiokisetan - 3,2'(5'black port) Torishi black (3.3.1.1 3 '7) decane] - 4-I le ⁇ Hue -Ruphosphate 'disodium salt (CDP-Star TM),
- luciferase activity in the immune complex can be measured by, for example, a luminescence method.
- a method for measuring luciferase activity by a luminescence method include a method in which luciferase is reacted with its substrate, and the luminescence intensity of generated luminescence is measured by a luminescence intensity meter or the like.
- the substrate of luciferase includes, for example, luciferin.
- the activity of j8-D-galactosidase in the immune complex can be measured by, for example, an absorbance method (colorimetric method).
- an absorbance method colorimetric method
- 13-D-galactosidase activity by an absorbance method colorimetric method
- a method of reacting cuctosidase with its substrate and measuring the absorbance of the reaction solution with a spectrophotometer or the like can be used.
- Substrates for j8-D-galactosidase include, for example, 2-chloro-4-nitrophenyl D-ratatoside, 2--trophenyl-j8-D-galactoside (ONPG), 5-bromo-4-chloro-3- Indolyl-13-D-galactoside (X-gal) and the like.
- the enzyme is glucose oxidase
- the glucose oxidase is allowed to act on glucose as a substrate, and the generated hydrogen peroxide is measured to determine the glucose oxidase activity in the immune complex. Can be measured.
- the measurement of hydrogen peroxide can be performed, for example, by the above-described method for measuring peroxidase activity.
- the above-mentioned buffers, metal ions, salts, saccharides, surfactants, preservatives, proteins, protein stabilizers and the like can coexist in the reaction.
- the reagent used in the immunoassay for quantifying the measurement target of the present invention includes a first antibody and an enzyme, which specifically bind to the measurement target, each having a binding number of 1: 1, 1: 2, and 1: 3. And an enzyme-labeled antibody substantially containing only one or more enzyme-labeled antibodies selected from the group consisting of enzyme-labeled antibodies in the ratio of 1: 1, to which the first antibody binds, if necessary It further contains a solid-phased antibody and a reagent for measuring Z or enzyme activity, wherein the separation means is bound to a second antibody that specifically binds to an antigen determination site different from the antigen determination site of the measurement target.
- the number of bonds between the first antibody and the enzyme is 1: 1, 1: 2 and 1 respectively.
- the labeled antibody may be a mixture of the enzyme-labeled antibody which is particularly preferable for the enzyme-labeled antibody having a binding power of 1: 1: about 1: 2.
- the ratio of the number of molecules of the enzyme-labeled antibody in which the number of bonds between the first antibody and the enzyme is 1: 1: 2 is preferably 50% or more of the total labeled antibodies, and 70% or more is more preferable. Preferred 90% or more is particularly preferred.
- An s3 ⁇ 4 drug containing an immobilized antibody, an enzyme-labeled antibody, and a reagent for measuring the activity of the labeled enzyme containing an immobilized antibody, an enzyme-labeled antibody, and a reagent for measuring the activity of the labeled enzyme.
- a reagent containing an immobilized antibody, an enzyme-labeled antibody, an IgG polymer, and a reagent for measuring the activity of the labeled enzyme is provided.
- a reagent containing an immobilized antibody, an enzyme-labeled antibody, mouse IgG, and a reagent for measuring the activity of a labeled enzyme is provided.
- a reagent containing an immobilized antibody, an enzyme-labeled antibody, an IgG polymer, mouse IgG, and a reagent for measuring the activity of the labeled enzyme is provided.
- a reagent comprising a solid-phased antibody, an enzyme-labeled antibody, an enzyme that inactivates an enzyme that labels the antibody, and a reagent for measuring the activity of the labeled enzyme.
- a reagent containing an immobilized antibody, an enzyme-labeled antibody, mouse IgG, an enzyme that inactivates the enzyme that labels the antibody, and a reagent for measuring the activity of the labeled enzyme is provided.
- a reagent comprising a solid-phased antibody, an enzyme-labeled antibody, an IgG polymer, an enzyme obtained by inactivating an enzyme labeling an antibody, and a reagent for measuring the activity of the labeled enzyme.
- a reagent containing an immobilized antibody, an enzyme-labeled antibody, mouse IgG, an IgG polymer, an enzyme that inactivates an enzyme that labels the antibody, and a reagent for measuring the activity of the labeled enzyme is provided.
- a reagent containing a solid-phased antibody, an enzyme-labeled antibody, a reagent for measuring the activity of a labeled enzyme, and a standard analyte • Reagent 10
- a reagent containing an immobilized antibody, an enzyme-labeled antibody, an IgG polymer, a reagent for measuring the activity of a labeled enzyme, and a standard substance to be measured is a reagent containing an immobilized antibody, an enzyme-labeled antibody, an IgG polymer, a reagent for measuring the activity of a labeled enzyme, and a standard substance to be measured.
- a reagent containing an immobilized antibody, an enzyme-labeled antibody, mouse IgG, a reagent for measuring the activity of a labeled enzyme, and a standard substance to be measured is a reagent containing an immobilized antibody, an enzyme-labeled antibody, mouse IgG, a reagent for measuring the activity of a labeled enzyme, and a standard substance to be measured.
- a reagent containing an immobilized antibody, an enzyme-labeled antibody, an IgG polymer, mouse IgG, a reagent for measuring the activity of a labeled enzyme, and a standard substance to be measured is a reagent containing an immobilized antibody, an enzyme-labeled antibody, an IgG polymer, mouse IgG, a reagent for measuring the activity of a labeled enzyme, and a standard substance to be measured.
- An immobilized antibody an enzyme-labeled antibody, an enzyme that inactivates an enzyme that labels an antibody, a reagent for measuring the activity of the labeled enzyme, and a reagent containing a standard analyte.
- Immobilized antibodies enzyme-labeled antibodies, mouse IgG, enzymes that inactivate the enzymes that label the antibodies, reagents for measuring the activity of the labeled enzymes, and reagents containing standard analytes
- An immobilized antibody an enzyme-labeled antibody, a mouse IgG, an IgG polymer, an enzyme that inactivates an enzyme that labels the antibody, a reagent for measuring the activity of the labeled enzyme, and a reagent containing a standard analyte.
- Examples of the reagent for measuring the activity of the labeled enzyme in the measurement reagent of the present invention include a reagent containing a substrate of the enzyme.
- Examples of the enzyme in the reagent for measuring enzyme activity include the aforementioned enzymes.
- Examples of the substrate include the aforementioned substrates.
- Examples of the standard substance to be measured in the measurement reagent of the present invention include, for example, an aqueous solution of the substance to be measured adjusted to a known concentration.
- the reagent for measurement of the present invention may be stored and transported in the form of a kit. If necessary, the above-mentioned buffers, metal ions, salts, saccharides, surfactants, preservatives, proteins and proteins may be used. It may contain a quality stabilizer and the like.
- Sulfuric acid manufactured by Kanto Chemical Co.
- FBS manufactured by HyClone NP-40: manufactured by Calbiochem
- POD stability buffer manufactured by Dakosite Masonry
- MAK33-IgGl / IgGl Poly manufactured by Roche Diagnostics
- HAMA serum type I manufactured by Roche Diagnostics
- HAMA serum type II manufactured by Roche Diagnostics
- the cryopreserved lymphoma cell line U937 (manufactured by Dainippon Pharmaceutical Co., Ltd.), which is known to secrete and express SIL-2R, is quickly thawed in a 37 ° C water bath, and transferred to a 15 mL sterile tube. 10 mL of ⁇ -MEM containing 10% FBS, penicillin and streptomycin was added and gently suspended. After centrifugation (1200 rpm) at room temperature for 5 minutes, the supernatant was removed by suction.
- the cell suspension obtained by adding 10 mL of the same medium to the residue and suspending the whole was transferred to a 25 cm 2 T flask, and cultured for 2 to 3 days in a carbon dioxide gas culture device (5% CO, 37 ° C). After that, 150cm 2 T
- Expansion culture was performed sequentially on Lasco and 225 cm 2 T flasks. After confirming that the cells are 100% confluent in the 225 cm 2 T flask, collect the culture supernatant in a sterilized container. The mixture was centrifuged (1200 rpm) at 4 ° C for 10 minutes. The supernatant obtained by centrifugation was transferred to a sterilized container, gently stirred for 15 minutes, and then filtered with a 0.2 m filter to obtain a standard substance for SIL-2R.
- the KTM-302 antibody was diluted with PBS to a final concentration of 4 / z g / mL, and 100 L of each was added to each well of a 96-well microtiter plate for solid phase. After standing at room temperature for 1 ⁇ , wash with blocking solution (10 mmol / L phosphate buffer containing 1% BSA, 5% saccharose, 0.05% Tween 20, 0.01% gentamicin sulfate, pH 7.2) and block. The solution was calcu- lated with 200 ⁇ L of calorie at room temperature for 1 ⁇ to block. After removing the blocking solution, the solution was dried in a vacuum dryer for 3 days to prepare an anti-SIL-2R monoclonal antibody-fixed solid phase (plate).
- F (Hitachi Ltd.) HPLC system (Hitachi, Ltd.) ab ') was separated and purified. 4 mg of the obtained F (ab ') was treated with 100 mmol / L borate buffer (pH 8.0).
- Coupling was achieved by the imide method.
- the molecular weight of F (ab ') antibody is about 92 kDa, and the molecular weight of POD is about 44 kDa. Therefore, the anti
- the molecular weight of the enzyme-labeled antibody which is l: l, is about 136 kDa, 1: 2 is about 180 kDa, 1: 3 is about 224 kDa, and 1: 4 is Approx. 268 kDa, approx. 312 kDa for 1: 5, approx. 228 kDa for 2: 1, approx. 272 kDa for 2: 2, approx. 316 kDa for 2: 3, approx. 3: 1 Is calculated to be about 320 kDa.
- the labeled antibody prepared by the method described in the above (1) was fractionated by an HPLC system (manufactured by Hitachi, Ltd.) using a G3000SW column (manufactured by Tosoichi; 21.5 mm x 60 cm). HPLC was performed at room temperature at a flow rate of 3 mL / min using a 0.1 mol / L phosphate buffer (pH 7.4) as a mobile phase. Fraction collection was performed with 3 mLZ fractions.
- the molecular weight marker is a high molecular weight gel filtration calibration kit (HMW Gel Filtration Calibration Kit, manufactured by Amersham Biosciences) and a low molecular weight gel filtration calibration kit (LMW Gel Filtration Calibration Kit, manufactured by Amersham NeuScience Science) )It was used.
- HMW Gel Filtration Calibration Kit manufactured by Amersham Biosciences
- LMW Gel Filtration Calibration Kit manufactured by Amersham NeuScience Science
- FIG. 1 shows the results of measuring the absorbance at 280 nm of each fraction. As shown in FIG. 1, peaks of absorbance were observed in 1) fraction 33, 2) fraction 40, 3) fraction 43, 4) fraction 48, and 5) fraction 52.
- the molecular weight of each fraction showing the above absorbance peak estimated by comparison with the molecular weight marker is 1) 250 kDa or more, 2) about 170 kDa, 3) about 140 kDa, 4) about 100 kDa, 5) It was about 40 kDa. Therefore, 1) the enzyme-labeled antibody in fraction 33 is a labeled antibody in which F (ab ') and POD are polymerized, 2) the enzyme-labeled antibody in fraction 40 is F (ab)
- a sample for electrophoresis was prepared so that the amount of protein derived from each of the fractions was 2 to 3 ⁇ gZ lane.
- Sample buffer for SDS-PAGE [8% SDS (Wako Pure Chemical Industries), 24% 2-mercaptoethanol (Nacalai Tester), and 40% glycerol (Kanto 1 mol / L Tris buffer solution (manufactured by Kagaku Co., Ltd., pH 6.8) was added in a 1/4 volume, and heated at 95 ° C for 5 minutes.
- the heat-treated sample is applied to an SDS-PAGE gel (Padier SPG-520L (manufactured by Atto)) using a 20 ⁇ LZ lane, electrophoresed at 20 mA per gel, and bands are detected in the usual manner. did.
- the molecular weight marker is a pre-stained Broad Range (Prestained Broad Range Bio-Rad, 250 kDa 150 kDa 100 kDa 75 kDa 50 kDa 37 kDa, 25 kDa, 16 kDa, 10 kDa )It was used.
- the enzyme-labeled antibodies in fraction 36 had F (ab ') and POD binding numbers of 1: 4 and 2: Yeast that is 2
- the enzyme-labeled antibody in the fraction-labeled antibody, fraction 37 has a reduced number of F (ab ')-POD bonds.
- the enzyme-labeled antibody in fraction 38 has a different number of bonds between F (ab ') and POD.
- Enzyme-labeled antibody with a force of S 1: 2 enzyme-labeled antibody in fraction 42, F (ab ') and POD
- the protein in fraction 47 is an enzyme-labeled compound having the number of bonds between F (ab ') and POD: 1
- Enzyme-labeled antibody diluent [150 mmol / L sodium chloride, 10% FBS, 0.2% NP-40, 100 ⁇ g / mL mouse IgG, 0.2% proxel GXL, 10% POD stabilization buffer and 0.16 g / mL POD (Roche Diagnostics, Inc. (2) was diluted with a 100 mmol / L acetate buffer solution (pH 6.0) containing the labeled iridani antibody solution (24-140 ng / l). mL) was added to each well, and the mixture was shaken at room temperature for 90 minutes using a horizontal rotary shaker (140 to 160 rpm).
- HAMA serum type I Lid. 92069721
- HAMA serum type II Lit. 14482684
- normal human serum Lit. 101001-2
- Fractions 32-35 which are high-molecular-weight, enzyme-labeled antibodies containing an antibody and an enzyme with a bond number of 1: 5, 2: 3, 3: 1, etc., respectively, contained SIL-2R in HAMA serum type I. The measured value of was over 1000 U / mL, and the fraction 32, which is considered to be highly polymerized, was as high as about 16 000 U / mL. Fraction 36, which was identified as having an antibody-enzyme binding force of 1: 4 or 2: 2, also showed significantly higher values.
- enzyme-labeled antibodies selected from the group consisting of enzyme-labeled antibodies in which the number of bonds between the antibody and the enzyme is 1: 3, 2: 1, 1: 2 and 1: 1 respectively It was shown that the enzyme-labeled antibody in fractions 38 to 46 that were identified as containing contained approximately 500 U / mL or less and suppressed the non-specific reaction of HAMA serum type I.
- the number of enzyme-labeled antibodies to which a small number of labeled enzyme molecules are bound per antibody molecule preferably the number of bonds between the first antibody and the enzyme is 1: 1, 1: 2, and 1 respectively.
- the enzyme-labeled antibody in fractions 40 to 46 prepared in Example 1 was diluted with enzyme-labeled antibody diluent (150 mmol / L sodium chloride, 10% FBS, 0.2% NP-40, mouse IgG, 0.2% proxel GXL). , 10% POD stabilizing buffer, diluted with 0.16 ⁇ g / mL POD 75 mmol / L MES buffer containing (Roche 'die ⁇ Diagnostics sticks Co.) (pH 6. 5)], the mouse IgG concentration It was adjusted to be 0, 20, 40, 60, 80, 100, 200 ⁇ g / mL, respectively.
- the measured value of HAMA serum type II when mouse IgG was not added was 9000 U / mL or more, and the nonspecific reaction caused by HAMA was caused by adding 20 g / mL mouse IgG. Non-specific reaction by AMA was suppressed and decreased to 437 U / mL.
- the measured value of the HAMA serum decreased, and the siL-2R value reached equilibrium with 80 ⁇ g / mL or more.
- the readings reached equilibrium at 80 g / mL, but no significant change was observed as in HAMA serotype II.
- Enzyme-labeled antibody in fractions 40 to 46 prepared in Example 1 was diluted with enzyme-labeled antibody (150 mmol / L sodium chloride, 10% FBS, 0.2% NP-40, 100 g / mL mouse IgG, high polymerization 75 mmol / L MES buffer containing mouse IgG, 0.2% proxel GXL, 10% POD stabilizing buffer and 0.16 g / mL POD (Roche Diagnostics), pH 6.5].
- enzyme-labeled antibody 150 mmol / L sodium chloride, 10% FBS, 0.2% NP-40, 100 g / mL mouse IgG, high polymerization 75 mmol / L MES buffer containing mouse IgG, 0.2% proxel GXL, 10% POD stabilizing buffer and 0.16 g / mL POD (Roche Diagnostics), pH 6.5].
- MAK33-IgGl / IgGl Poly was used as the polymerized mouse IgG, the enzyme-labeled antibody solution was used so that the concentrations were 0, 75, 100, 125, 150, 175, 200, and 300 g / mL, respectively. Prepared.
- MAK33-IgG (2b) / Fab (2a) Poly was used as the mouse IgG for polymerization, enzyme labeling was performed so that the concentrations were 0, 5, 50, and 100 ⁇ g / mL, respectively.
- Antibodies were prepared.
- HAMA serum type I Lit. 90643629
- HAMA serum type II Lit. 92069831
- normal human serum Lit. 1 Measured in the same manner as (5).
- Table 3 shows the effect of adding MAK33-IgGl / IgGl Poly.
- Table 4 shows the effect of adding MAK33-IgG (2b) / Fab (2a) Poly.
- the enzyme-labeled antibodies in fractions 40 to 46 prepared in Example 1 were diluted with a labeled antibody diluent (150 mmol / L sodium chloride, 10% FBS, 0.2% NP-40, 100 ⁇ g / mL mouse IgG, 200 ⁇ L g / mL MAK33- IgGl / IgGl Poly, 0.2% proxel GXL, 10% POD stabilizing buffer and 75 mmol / L MES buffer containing 0.16 ⁇ g / mL POD, pH 6.5).
- a labeled antibody diluent 150 mmol / L sodium chloride, 10% FBS, 0.2% NP-40, 100 ⁇ g / mL mouse IgG, 200 ⁇ L g / mL MAK33- IgGl / IgGl Poly, 0.2% proxel GXL, 10% POD stabilizing buffer and 75 mmol / L MES buffer containing 0.16 ⁇ g / m
- Example 4 the enzyme-labeled antibody solution prepared above, and reagents other than the enzyme-labeled antibody solution used in the method described in Example 1 (4) (the immobilized plate prepared in Reference Example 3, Example 1 ( The standard substance solution, washing solution, OPD solution and reaction stop solution of 4) are collectively referred to as “the reagent of Example 4.”
- the composition of the reagent of Example 4 is described below.
- Standard substance solution Standard substance solutions containing sIL-2R at 0 U / mL, 200 U / mL, 400 U / mL, 1600 U / mL, 3200 U / mL, and 6400 U / mL (150 mmol / L sodium chloride, 4% BSA, (10 mmol / L phosphate buffer containing 1% saccharose and 0.01% BioAce, pH 7.5)
- Enzyme-labeled antibody solution Predetermined amount (24-140 ng / mL) of fraction 40-46 of Example 1
- Labeled antibody diluent containing OD-labeled antibody 150 mmol / L sodium chloride, 10% FBS, 0.2% NP-40, 100 ⁇ g / mL mouse IgG, 200 ⁇ g / mL MAK33—Iggl / (75 mmo 1 / L MES buffer containing IgGl Poly, 0.2% proxel GXL, 10% POD stable buffer
- Wash solution 150 mmol / L sodium chloride, 10 mmol / L phosphate buffer containing 0.05% Tween 20, pH 6.8
- OPD solution 2 mg / mL OPD, 0.75 g / L urea hydrogen peroxide, 100 mmol / L phosphate-citrate buffer containing 0.01% procrine 300, pH 4.4
- SIL-2R in each serum was also measured using Imuraz IL-2R (manufactured by DPC). Table 5 shows the results.
- the sIL-2R of a sample obtained by adding HAMA serum to normal human serum at different amounts was measured, and HAMA ⁇ The effect of concentration on the measured values was investigated.
- HAMA serum type I Lit. 90643656
- HAMA serum type I KLot. HAMA was measured using a sandwich ELISA kit for HAMA measurement, ImmuSTRIP HAMA Fragment (manufactured by Imnomedics).
- HAMA serotype I when measured with the reagent of Example 4, even if the HAMA concentration was increased to 65.3 ⁇ g / mL (2.5 times that of HAMA contained in commercially available HAMA serotype I), it was still measured. The effect rate of the measurement was 10% or less. When measured with the Imimrise IL-2R, the effect on the measured value was found to be 30-40%, indicating that HAMA was affected. When HAMA serum type II was measured using the reagent of Example 4, the measurement was performed even when the HAMA concentration was increased to 31.1 ⁇ g / mL (2.5 times that of HAMA contained in ⁇ sales ⁇ AMA serotype)).
- a reagent kit comprising the following reagents was constructed.
- Composition labeled antibody diluent (150 mmol / L sodium chloride, 10% FBS, 0.2% NP-) containing a predetermined amount (24-140 ng / mL) of POD-labeled antibody in fractions 40-46 of Example 1 40, 100 ⁇ g / mL mouse IgG, 200 ⁇ g / mL ⁇ 33-IgGl / IgGl Poly, 0.2% proxel GXL ⁇ 75 mmol / L MES containing 10% POD stabilization buffer and 0.16 g / mL POD (Buffer, pH 6.5)
- Composition 10 mmol / L phosphate buffer (pH7.45) containing 150 mmol / L sodium chloride, 4% BSA, 1% saccharose, 0.2% proxel GXL and 20 g / mL mouse IgG
- Composition 100 mmol / L containing 0.75 g / L urea hydrogen peroxide and 0.1% procrine 300 L-Phosphate-monocitrate buffer (pH 4.4)
- composition 1 mol / L sulfuric acid
- Sample A a human serum
- a sample diluent (10 mmol / L phosphate buffer containing 50 mmol / L sodium chloride, 4% BSA, 1% saccharose, 0.2% proxel GXL and g / mL mouse IgG).
- concentration of each sIL-2R was measured using the reagent of Example 4.
- Table 9 shows the measured values and the calculated values of SIL-2R of the sample stock solution obtained from the measured values and the dilution ratio. The calculated SIL-2R values of the sample stock solution differed depending on the dilution ratio, indicating that the dilution linearity was poor and a nonspecific reaction occurred.
- Sample A is diluted 1/2, 1/4, 1/6, 1/11, 1/21, 1/31 with the sample diluent, and labeled by the periodic acid method, consisting of the components shown below.
- SIL-2R was measured using the SIL-2R measurement reagent (hereinafter referred to as SIL-2R measurement reagent B) using the POD-labeled antibody obtained, and the SIL-2R of the sample stock solution was determined from the measured value and the dilution ratio. The calculated value was determined.
- the SIL-2R measurement reagent B had the same configuration as the reagent of Example 4 except for the enzyme-labeled antibody solution, and the POD-labeled antibody was not separated by gel filtration.
- Anti-sIL-2R antibody-immobilized plate 96 well microtiter plate with 8 wells x 12 strips on which 4 / z g / mL KTM-302 antibody was immobilized at 100 ⁇ L / well
- Standard solution 0 U / mL, 200 U / mL, 400 U / mL, 1600 U / mL, 3200 U / mL, 6400 U / mL Standard solution containing sIL-2R (150 mmol / L sodium chloride, 4% BSA, 1% 10 mmol / L phosphate buffer, pH 7.5 containing saccharose and 0.01% bioacease, pH 7.5)
- Enzyme-labeled antibody solution POD labeling with the specified amount (24-140 ng / mL) by the periodate method
- Antibody-containing labeled antibody diluent 150 mmol / L sodium chloride, 10% FBS, 0.2% NP-40, 20 ⁇ g / mL mouse IgG, 0.2% proxel GXL, 10% POD stabilizing buffer and (10 mmol / L phosphate buffer containing 0.16 ⁇ g / mL POD, pH 7.5)
- Wash solution 150 mmol / L sodium chloride, 10 mmol / L phosphoric acid containing 0.05% Tween 20 Buffer, pH 6.8
- OPD solution 2 mg / mL OPD, 0.75 g / L urea hydrogen peroxide, 100 mmol / L phosphate-citrate buffer containing 0.01% procrine 300, pH 4.4
- the measured value with the reagent B for measuring SIL-2R was about 4 times that of the reagent of Example 4.
- the reagent of Example 4 has a dilution ratio of 1/8.
- SIL-2R reagent B a nonspecific reaction of 125% of the theoretical value was observed even at a dilution ratio of 1/11, while the effect of the nonspecific reaction was almost eliminated.
- a dilution of 1/21 to 1/31 was required to eliminate.
- a POD-labeled antibody labeled with the periodic acid method used in the si L-2R measurement reagent B! Is a single antibody molecule, such as a 1: 4 or 1: 5 binding force between the antibody and POD. It is considered that the number of POD bonds per unit is high, and that the number of antibodies and the number of POD bonds are 3 ⁇ 4: 2, 2: 3 and 3: 1.
- the sIL-2R measurement value of the sample A diluted 1/4 with the reagent of Example 4 was 2022 U / mL, and a non-specific reaction was observed as compared with the theoretical value.However, MAK33-IgG Poly Alternatively, the addition of Inactive Poly-POD reduced the measured value to near the theoretical value, further suppressing nonspecific reactions. In particular, non-specific reactions were almost completely suppressed by the addition of Inactive Poly-POD to the mixture, indicating that non-specific reactions caused by antibodies reacting with POD were present.
- the reagent of Example 4 can suppress the non-specific reaction of sample A, that is, the non-specific reaction caused by the antibody that reacts with POD, and furthermore, the co-presence of inactivated POD allows the anti-POD antibody It was possible to sufficiently suppress the non-specific reaction caused by this.
- an immunological quantification method and a quantification reagent for an object to be measured in a sample which are useful for monitoring a disease state, diagnosing a disease, and the like, and a method for suppressing a nonspecific reaction in the immunological quantification method.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006514609A JP4866724B2 (ja) | 2004-06-14 | 2005-06-14 | 非特異反応が抑制された免疫測定方法および試薬 |
EP05751289A EP1767942A4 (en) | 2004-06-14 | 2005-06-14 | IMMUNOENZYMATIC ASSAY METHOD HAVING INHIBITED NON-SPECIFIC REACTION AND REAGENT THEREFOR |
CN2005800195973A CN1969189B (zh) | 2004-06-14 | 2005-06-14 | 非特异性反应被抑制的可溶性白介素-2受体免疫学测定方法和试剂 |
KR1020067026120A KR101233837B1 (ko) | 2004-06-14 | 2005-06-14 | 비특이 반응이 억제된 면역 측정 방법 및 시약 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-176288 | 2004-06-14 | ||
JP2004176288 | 2004-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005121795A1 true WO2005121795A1 (ja) | 2005-12-22 |
Family
ID=35503204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/010882 WO2005121795A1 (ja) | 2004-06-14 | 2005-06-14 | 非特異反応が抑制された免疫測定方法および試薬 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1767942A4 (ja) |
JP (2) | JP4866724B2 (ja) |
KR (1) | KR101233837B1 (ja) |
CN (1) | CN1969189B (ja) |
TW (1) | TW200604527A (ja) |
WO (1) | WO2005121795A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008201968A (ja) * | 2007-02-22 | 2008-09-04 | Asahi Kasei Pharma Kk | ロイコ色素の安定化方法 |
JP2008281489A (ja) * | 2007-05-11 | 2008-11-20 | Fujirebio Inc | 不活化アルカリフォスファターゼの製造方法及び酵素免疫測定用の精度向上剤 |
JP2008292474A (ja) * | 2007-04-27 | 2008-12-04 | Nationa Hospital Organization | 成人t細胞白血病発症リスク判定方法 |
JP2010230660A (ja) * | 2009-03-06 | 2010-10-14 | Kyowa Medex Co Ltd | 可溶性インターロイキン−2受容体定量用標準品 |
JP2011007782A (ja) * | 2009-05-22 | 2011-01-13 | Kyowa Medex Co Ltd | 可溶性インターロイキン−2受容体の測定方法及び測定用試薬 |
US8080423B2 (en) | 2004-08-05 | 2011-12-20 | Asahi Kasei Pharma Corporation | Reagent containing protease reaction promoter and/or colorant stabilizer |
JPWO2014051144A1 (ja) * | 2012-09-28 | 2016-08-25 | 積水メディカル株式会社 | 免疫学的検出方法および免疫学的検出試薬 |
JP2017191012A (ja) * | 2016-04-13 | 2017-10-19 | 株式会社Lsiメディエンス | 可溶性インターロイキン2受容体の免疫学的測定法 |
CN110824159A (zh) * | 2019-11-22 | 2020-02-21 | 蓝怡科技集团股份有限公司 | 一种碱性磷酸酶标记物的稀释液及其应用 |
US11422128B2 (en) | 2016-04-13 | 2022-08-23 | Lsi Medience Corporation | Immunoassay employing sulfated polysaccharide |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101995459A (zh) * | 2009-08-26 | 2011-03-30 | 刘萍 | 包被板封闭液 |
CN103616507B (zh) * | 2013-12-11 | 2015-08-19 | 山东博科生物产业有限公司 | 无蛋白包被板封闭液 |
KR101619862B1 (ko) * | 2014-09-30 | 2016-05-12 | 주식회사 녹십자 | 간접효소면역측정법을 이용하는 인간 Fc 포함 단백질의 역가 측정키트 및 이를 이용한 Fc 포함 단백질의 역가 측정방법 |
CN107923907B (zh) | 2015-08-28 | 2020-05-29 | 荣研化学株式会社 | 免疫学的测定用试剂组合物及其用途 |
WO2017057622A1 (ja) * | 2015-09-29 | 2017-04-06 | 積水メディカル株式会社 | 免疫測定用抗体とその作製方法 |
JP6765232B2 (ja) | 2016-06-30 | 2020-10-07 | シスメックス株式会社 | 免疫複合体転移法により被検物質を検出するための抗体試薬及びその製造方法、並びにその抗体試薬の利用 |
CN108761064A (zh) * | 2018-05-21 | 2018-11-06 | 苏州佑君环境科技有限公司 | 一种辣根过氧化物酶标记抗体用稀释液及其制备方法 |
CN108956973A (zh) * | 2018-05-21 | 2018-12-07 | 苏州佑君环境科技有限公司 | 一种多功能抗体稀释液及其制备方法 |
CN113325172B (zh) * | 2020-02-28 | 2022-02-11 | 深圳市亚辉龙生物科技股份有限公司 | 新型冠状病毒检测试剂盒 |
CN112114128B (zh) * | 2020-09-24 | 2023-08-29 | 武汉生之源生物科技股份有限公司 | 一种封闭剂及其制备方法 |
CN112557669A (zh) * | 2020-09-30 | 2021-03-26 | 杭州华视诺维医疗科技有限公司 | 一种试剂盒及其在检测前房液中血管内皮生长因子中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6270761A (ja) * | 1985-04-19 | 1987-04-01 | アメリカ合衆国 | 疾患指示体としての可溶性インタ−ロイキン−2レセプタ及びその試験法 |
JPH05188055A (ja) * | 1991-07-05 | 1993-07-27 | Takeda Chem Ind Ltd | 酵素免疫測定法における非特異的反応の抑制法 |
JP2001183375A (ja) * | 1999-12-27 | 2001-07-06 | Tosoh Corp | 酵素標識抗体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5035088B1 (ja) * | 1971-06-01 | 1975-11-13 | ||
US4256833A (en) * | 1979-01-08 | 1981-03-17 | Majid Ali | Enzyme immunoassay for allergic disorders |
US4914040A (en) * | 1988-03-03 | 1990-04-03 | Boehringer Mannheim Gmbh | Reagent and method for determination of a polyvalent substance using an immunoaggregate |
DE4227102C2 (de) * | 1992-08-17 | 2002-11-14 | Dade Behring Marburg Gmbh | Immunchemisches Verfahren zum Nachweis eines Analyten |
JPH07270414A (ja) * | 1994-03-31 | 1995-10-20 | Toray Ind Inc | 高感度酵素免疫測定法 |
DE19828466A1 (de) * | 1998-06-26 | 1999-12-30 | Roche Diagnostics Gmbh | Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind |
US7541150B2 (en) * | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
-
2005
- 2005-06-14 EP EP05751289A patent/EP1767942A4/en not_active Withdrawn
- 2005-06-14 KR KR1020067026120A patent/KR101233837B1/ko not_active IP Right Cessation
- 2005-06-14 JP JP2006514609A patent/JP4866724B2/ja active Active
- 2005-06-14 CN CN2005800195973A patent/CN1969189B/zh not_active Expired - Fee Related
- 2005-06-14 TW TW094119577A patent/TW200604527A/zh unknown
- 2005-06-14 WO PCT/JP2005/010882 patent/WO2005121795A1/ja active Application Filing
-
2011
- 2011-07-01 JP JP2011147178A patent/JP5559747B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6270761A (ja) * | 1985-04-19 | 1987-04-01 | アメリカ合衆国 | 疾患指示体としての可溶性インタ−ロイキン−2レセプタ及びその試験法 |
JPH05188055A (ja) * | 1991-07-05 | 1993-07-27 | Takeda Chem Ind Ltd | 酵素免疫測定法における非特異的反応の抑制法 |
JP2001183375A (ja) * | 1999-12-27 | 2001-07-06 | Tosoh Corp | 酵素標識抗体 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1767942A4 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8080423B2 (en) | 2004-08-05 | 2011-12-20 | Asahi Kasei Pharma Corporation | Reagent containing protease reaction promoter and/or colorant stabilizer |
JP2008201968A (ja) * | 2007-02-22 | 2008-09-04 | Asahi Kasei Pharma Kk | ロイコ色素の安定化方法 |
JP4697809B2 (ja) * | 2007-02-22 | 2011-06-08 | 旭化成ファーマ株式会社 | ロイコ色素の安定化方法 |
US8268017B2 (en) | 2007-02-22 | 2012-09-18 | Asahi Kasei Pharma Corporation | Method for stabilizing leuco-type colorant |
JP2008292474A (ja) * | 2007-04-27 | 2008-12-04 | Nationa Hospital Organization | 成人t細胞白血病発症リスク判定方法 |
JP2013083671A (ja) * | 2007-04-27 | 2013-05-09 | Nationa Hospital Organization | くすぶり型又は慢性型の成人t細胞白血病患者の急性転化後の治療方針を決定するための方法 |
JP2008281489A (ja) * | 2007-05-11 | 2008-11-20 | Fujirebio Inc | 不活化アルカリフォスファターゼの製造方法及び酵素免疫測定用の精度向上剤 |
JP2014167490A (ja) * | 2009-03-06 | 2014-09-11 | Kyowa Medex Co Ltd | 可溶性インターロイキン−2受容体定量用標準品 |
JP2010230660A (ja) * | 2009-03-06 | 2010-10-14 | Kyowa Medex Co Ltd | 可溶性インターロイキン−2受容体定量用標準品 |
JP2011007782A (ja) * | 2009-05-22 | 2011-01-13 | Kyowa Medex Co Ltd | 可溶性インターロイキン−2受容体の測定方法及び測定用試薬 |
JP2014186041A (ja) * | 2009-05-22 | 2014-10-02 | Kyowa Medex Co Ltd | 可溶性インターロイキン−2受容体の測定方法及び測定用試薬 |
JP2015132631A (ja) * | 2009-05-22 | 2015-07-23 | 協和メデックス株式会社 | 可溶性インターロイキン−2受容体の測定方法及び測定用試薬 |
JPWO2014051144A1 (ja) * | 2012-09-28 | 2016-08-25 | 積水メディカル株式会社 | 免疫学的検出方法および免疫学的検出試薬 |
JP2017191012A (ja) * | 2016-04-13 | 2017-10-19 | 株式会社Lsiメディエンス | 可溶性インターロイキン2受容体の免疫学的測定法 |
US11422128B2 (en) | 2016-04-13 | 2022-08-23 | Lsi Medience Corporation | Immunoassay employing sulfated polysaccharide |
CN110824159A (zh) * | 2019-11-22 | 2020-02-21 | 蓝怡科技集团股份有限公司 | 一种碱性磷酸酶标记物的稀释液及其应用 |
Also Published As
Publication number | Publication date |
---|---|
JP4866724B2 (ja) | 2012-02-01 |
JP5559747B2 (ja) | 2014-07-23 |
CN1969189A (zh) | 2007-05-23 |
KR101233837B1 (ko) | 2013-02-15 |
CN1969189B (zh) | 2012-03-21 |
TW200604527A (en) | 2006-02-01 |
JP2011197014A (ja) | 2011-10-06 |
KR20070026576A (ko) | 2007-03-08 |
JPWO2005121795A1 (ja) | 2008-04-10 |
EP1767942A4 (en) | 2008-07-16 |
EP1767942A1 (en) | 2007-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005121795A1 (ja) | 非特異反応が抑制された免疫測定方法および試薬 | |
CA2668001C (en) | A method of immunoassaying a component to be measured in a sample containing hemoglobin | |
US9274125B2 (en) | Method and kit for measuring component in the presence of fatty acid alkanolamide or nonionic polyoxyethylene surfactant | |
US20190376961A1 (en) | Method for Measuring Fibroblast Growth Factor-23 and Reagent Therefor | |
JP6042937B2 (ja) | 可溶性インターロイキン−2受容体の測定方法及び測定用試薬 | |
JP2022058732A (ja) | 線維芽細胞増殖因子-23の測定方法、測定試薬及び測定キット | |
EP4010704A1 (en) | An improved autoantibody detection assay | |
JP7084590B2 (ja) | 脂質異常症治療が必要な被検者の選別方法及び選別用試薬 | |
JP2007225603A (ja) | 試料中の測定対象物の免疫測定方法および免疫測定試薬 | |
WO2017159473A1 (ja) | 慢性腎臓病患者における高リン血症の発症のしやすさを試験する方法 | |
JP5902714B2 (ja) | 検体中の測定対象物の連続的免疫測定法における非特異反応抑制方法 | |
JP2015212237A (ja) | 新規ペプチドおよびその使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006514609 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067026120 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580019597.3 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005751289 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067026120 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005751289 Country of ref document: EP |